Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer

Takaomi Hagi, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Naohiro Nishida, Daisuke Sakai, Masaaki Motoori, Yutaka Kimura, Taroh Satoh, Masaki Mori, Yuichiro Doki

研究成果: ジャーナルへの寄稿記事

抄録

Background: Dysphagia is a major symptom of esophageal cancer (EC) that significantly affects patient quality of life; however, little is known regarding its clinical impact on the treatment course in patients with EC. Methods: This retrospective study included 434 consecutive patients with EC who received docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy as an initial treatment. We evaluated the relationships between the dysphagia score at diagnosis and clinicopathological factors, including DCF therapy-related adverse events, tumor response, and survival. Results: The dysphagia scores were 0 in 208 patients (47.9%), 1 in 82 patients (18.9%), 2 in 52 patients (12.0%), 3 in 59 patients (13.6%), and 4 in 33 patients (7.6%). High (≥ 3) dysphagia scores were significantly associated with high incidences of grade 3/4 febrile neutropenia (FN) (79.3 vs. 35.7%, P < 0.001) and diarrhea (63.0 vs. 28.1%, P < 0.001) compared with low (≤ 2) scores. Logistic regression analysis further identified the dysphagia scores as an independent predictor of both FN and severe diarrhea during DCF chemotherapy. Furthermore, compared with low scores, high dysphagia scores were associated with a worse clinical response to chemotherapy (response rate 65.2 vs. 78.7%, P = 0.008) and worse 5-year overall survival (35.4 vs. 56.4%, P = 0.001). Conclusions: The dysphagia score at diagnosis was an independent predictor of FN and severe diarrhea. Furthermore, this score might be useful in predicting chemotherapy response and long-term survival in patients treated with DCF.

元の言語英語
ページ(範囲)4754-4764
ページ数11
ジャーナルAnnals of Surgical Oncology
26
発行部数13
DOI
出版物ステータス出版済み - 12 1 2019

Fingerprint

Esophageal Neoplasms
Deglutition Disorders
docetaxel
Drug Therapy
Fluorouracil
Febrile Neutropenia
Cisplatin
Diarrhea
Survival
Therapeutics
Retrospective Studies
Logistic Models
Regression Analysis
Quality of Life
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

これを引用

Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. / Hagi, Takaomi; Makino, Tomoki; Yamasaki, Makoto; Tanaka, Koji; Nishida, Naohiro; Sakai, Daisuke; Motoori, Masaaki; Kimura, Yutaka; Satoh, Taroh; Mori, Masaki; Doki, Yuichiro.

:: Annals of Surgical Oncology, 巻 26, 番号 13, 01.12.2019, p. 4754-4764.

研究成果: ジャーナルへの寄稿記事

Hagi, T, Makino, T, Yamasaki, M, Tanaka, K, Nishida, N, Sakai, D, Motoori, M, Kimura, Y, Satoh, T, Mori, M & Doki, Y 2019, 'Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer', Annals of Surgical Oncology, 巻. 26, 番号 13, pp. 4754-4764. https://doi.org/10.1245/s10434-019-07744-7
Hagi, Takaomi ; Makino, Tomoki ; Yamasaki, Makoto ; Tanaka, Koji ; Nishida, Naohiro ; Sakai, Daisuke ; Motoori, Masaaki ; Kimura, Yutaka ; Satoh, Taroh ; Mori, Masaki ; Doki, Yuichiro. / Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. :: Annals of Surgical Oncology. 2019 ; 巻 26, 番号 13. pp. 4754-4764.
@article{2a5631e388cc4e36a5f370ee7b527000,
title = "Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer",
abstract = "Background: Dysphagia is a major symptom of esophageal cancer (EC) that significantly affects patient quality of life; however, little is known regarding its clinical impact on the treatment course in patients with EC. Methods: This retrospective study included 434 consecutive patients with EC who received docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy as an initial treatment. We evaluated the relationships between the dysphagia score at diagnosis and clinicopathological factors, including DCF therapy-related adverse events, tumor response, and survival. Results: The dysphagia scores were 0 in 208 patients (47.9{\%}), 1 in 82 patients (18.9{\%}), 2 in 52 patients (12.0{\%}), 3 in 59 patients (13.6{\%}), and 4 in 33 patients (7.6{\%}). High (≥ 3) dysphagia scores were significantly associated with high incidences of grade 3/4 febrile neutropenia (FN) (79.3 vs. 35.7{\%}, P < 0.001) and diarrhea (63.0 vs. 28.1{\%}, P < 0.001) compared with low (≤ 2) scores. Logistic regression analysis further identified the dysphagia scores as an independent predictor of both FN and severe diarrhea during DCF chemotherapy. Furthermore, compared with low scores, high dysphagia scores were associated with a worse clinical response to chemotherapy (response rate 65.2 vs. 78.7{\%}, P = 0.008) and worse 5-year overall survival (35.4 vs. 56.4{\%}, P = 0.001). Conclusions: The dysphagia score at diagnosis was an independent predictor of FN and severe diarrhea. Furthermore, this score might be useful in predicting chemotherapy response and long-term survival in patients treated with DCF.",
author = "Takaomi Hagi and Tomoki Makino and Makoto Yamasaki and Koji Tanaka and Naohiro Nishida and Daisuke Sakai and Masaaki Motoori and Yutaka Kimura and Taroh Satoh and Masaki Mori and Yuichiro Doki",
year = "2019",
month = "12",
day = "1",
doi = "10.1245/s10434-019-07744-7",
language = "English",
volume = "26",
pages = "4754--4764",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "13",

}

TY - JOUR

T1 - Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer

AU - Hagi, Takaomi

AU - Makino, Tomoki

AU - Yamasaki, Makoto

AU - Tanaka, Koji

AU - Nishida, Naohiro

AU - Sakai, Daisuke

AU - Motoori, Masaaki

AU - Kimura, Yutaka

AU - Satoh, Taroh

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Dysphagia is a major symptom of esophageal cancer (EC) that significantly affects patient quality of life; however, little is known regarding its clinical impact on the treatment course in patients with EC. Methods: This retrospective study included 434 consecutive patients with EC who received docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy as an initial treatment. We evaluated the relationships between the dysphagia score at diagnosis and clinicopathological factors, including DCF therapy-related adverse events, tumor response, and survival. Results: The dysphagia scores were 0 in 208 patients (47.9%), 1 in 82 patients (18.9%), 2 in 52 patients (12.0%), 3 in 59 patients (13.6%), and 4 in 33 patients (7.6%). High (≥ 3) dysphagia scores were significantly associated with high incidences of grade 3/4 febrile neutropenia (FN) (79.3 vs. 35.7%, P < 0.001) and diarrhea (63.0 vs. 28.1%, P < 0.001) compared with low (≤ 2) scores. Logistic regression analysis further identified the dysphagia scores as an independent predictor of both FN and severe diarrhea during DCF chemotherapy. Furthermore, compared with low scores, high dysphagia scores were associated with a worse clinical response to chemotherapy (response rate 65.2 vs. 78.7%, P = 0.008) and worse 5-year overall survival (35.4 vs. 56.4%, P = 0.001). Conclusions: The dysphagia score at diagnosis was an independent predictor of FN and severe diarrhea. Furthermore, this score might be useful in predicting chemotherapy response and long-term survival in patients treated with DCF.

AB - Background: Dysphagia is a major symptom of esophageal cancer (EC) that significantly affects patient quality of life; however, little is known regarding its clinical impact on the treatment course in patients with EC. Methods: This retrospective study included 434 consecutive patients with EC who received docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy as an initial treatment. We evaluated the relationships between the dysphagia score at diagnosis and clinicopathological factors, including DCF therapy-related adverse events, tumor response, and survival. Results: The dysphagia scores were 0 in 208 patients (47.9%), 1 in 82 patients (18.9%), 2 in 52 patients (12.0%), 3 in 59 patients (13.6%), and 4 in 33 patients (7.6%). High (≥ 3) dysphagia scores were significantly associated with high incidences of grade 3/4 febrile neutropenia (FN) (79.3 vs. 35.7%, P < 0.001) and diarrhea (63.0 vs. 28.1%, P < 0.001) compared with low (≤ 2) scores. Logistic regression analysis further identified the dysphagia scores as an independent predictor of both FN and severe diarrhea during DCF chemotherapy. Furthermore, compared with low scores, high dysphagia scores were associated with a worse clinical response to chemotherapy (response rate 65.2 vs. 78.7%, P = 0.008) and worse 5-year overall survival (35.4 vs. 56.4%, P = 0.001). Conclusions: The dysphagia score at diagnosis was an independent predictor of FN and severe diarrhea. Furthermore, this score might be useful in predicting chemotherapy response and long-term survival in patients treated with DCF.

UR - http://www.scopus.com/inward/record.url?scp=85071416625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071416625&partnerID=8YFLogxK

U2 - 10.1245/s10434-019-07744-7

DO - 10.1245/s10434-019-07744-7

M3 - Article

C2 - 31452051

AN - SCOPUS:85071416625

VL - 26

SP - 4754

EP - 4764

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 13

ER -